Condition: CAR T-cell Therapy · Autoimmune Hemolytic Anemia · Brain Function · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Cell therapy is an innovative treatment with significant efficacy in hematologic and certain autoimmune diseases. Although it offers potential benefits for autoimmune hemolytic anemia (AIHA), it may result in cognitive and other potential impairments, which can adversely affect patients' cognition and behavior. Brain function and psychological assessment are essential for the early detection of potential impairments, allowing timely interventions to prevent complications and ensure patient safety. This study aims to comprehensively evaluate the physical and psychological impacts of cell therapy on AIHA patients to develop safer and more effective treatment strategies that enhance their quality of life.
This description comes directly from the study's public registry record.
Zhexiang Kuang, MSN · 13920361752 · kuangzhexiang@ihcams.ac.cn
Xiao Yu, Undergraduate · 18722218448 · yuxiao@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Regenerative Medicine Center | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06921980